Cel-Sci Corporation (CVM)

NYSEAMERICAN: CVM · IEX Real-Time Price · USD
4.42
-0.03 (-0.67%)
Jun 29, 2022 4:00 PM EDT - Market closed
-0.67%
Market Cap 191.51M
Revenue (ttm) n/a
Net Income (ttm) -36.01M
Shares Out 43.33M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 243,494
Open 4.36
Previous Close 4.45
Day's Range 4.22 - 4.44
52-Week Range 2.49 - 12.90
Beta 2.16
Analysts Buy
Price Target 15.30 (+246.2%)
Earnings Date Aug 15, 2022

About CVM

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]

Industry Biotechnology
IPO Date Jan 1, 1987
CEO Geert Kersten
Country United States
Stock Exchange NYSEAMERICAN
Ticker Symbol CVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CVM stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 246.15% from the latest price.

Price Target
$15.3
(246.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CEL-SCI Corporation to Present at LD Micro Invitational

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation to Present at LD Micro Invitational.

CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ASCO22--CEL-SCI presents Phase 3 Multikine head and neck cancer data at ASCO.

CEL-SCI Announces Publication of ASCO 2022 Abstracts

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces publication of ASCO 2022 abstracts.

CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation reports second quarter fiscal 2022 financial results.

CEL-SCI Announces Acceptance of Abstracts to ASCO 2022

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces acceptance of abstracts to ASCO 2022.

3 Penny Stocks to Watch With Above Average Volume Today

Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today  appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols: AGRIVSTM

CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports first quarter fiscal 2022 financial results.

CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2021 financial results and clinical & corporate developments.

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation completes commercial-scale buildout of Multikine manufacturing facility.

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.

Why CEL-SCI Stock Soared Today

The company attempted to clarify "confusion" related to its recent late-stage clinical results.

CEL-SCI Corporation Issues Letter to Shareholders

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--CEL-SCI Corporation issues letter to shareholders.

3 Biotechs to Avoid Like the Plague in July

Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.

Other symbols: CYDYNWBO

Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.

Why CEL-SCI Shares Are Getting Hammered Today

CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups...

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

Will All End Well for This Popular Reddit Biotech?

Everything went the wrong way for Cel-Sci.

CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today

Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appeare...

CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients

CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In th...

CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group R...

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Multikine immunotherapy produces significant 14.1% 5-Year survival benefit in group receiving surgery plus radiotherapy in landmark Phase 3 Study.

CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation invites participants to pre-submit questions for Annual Shareholder Meeting.

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.

CEL-SCI Stock Drops After Raising $37.1M Via Secondary Equity Offering

CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount ...

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.

CEL-SCI Announces Bought Deal Offering

VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering